---
title: "Jolly: The research and development work on the Parkinson's pipeline LY-N001 of Lingyi Biotech is ongoing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256240879.md"
description: "Jolly stated in an institutional survey that the research and development work for Lingyi Biotech's Parkinson's pipeline LY-N001 is ongoing, with major preclinical studies completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with plans for IND applications and clinical research in China and the United States in the future. Lingyi Biotech focuses on the research and development of innovative drugs for single-gene genetic diseases and plans to increase its capital by 20 million yuan in April 2025"
datetime: "2025-09-07T01:10:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256240879.md)
  - [en](https://longbridge.com/en/news/256240879.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256240879.md)
---

# Jolly: The research and development work on the Parkinson's pipeline LY-N001 of Lingyi Biotech is ongoing

Jolly stated during an institutional research that the R&D work for Lingyi Biotech's Parkinson's pipeline LY-N001 is ongoing, and the main preclinical research has been completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with future goals of applying for IND in China and the U.S. and conducting clinical research and global market layout. Lingyi Biotech is a company focused on innovative drug development for single-gene genetic diseases, positioned to develop gene therapy drugs with differentiated advantages. The company increased its investment in Lingyi Biotech by 20 million yuan in April 2025

### Related Stocks

- [300181.CN](https://longbridge.com/en/quote/300181.CN.md)

## Related News & Research

- [Baidu: AI Cloud Infra and GPU cloud drove growth and margin gains despite overall revenue decline](https://longbridge.com/en/news/296242242.md)
- [Demant hearing care chief Niels Wagner sells shares worth DKK 1.47 million](https://longbridge.com/en/news/296345010.md)
- [Baidu: AI-powered business growth offset revenue decline, with strong cash flow and global expansion](https://longbridge.com/en/news/296208127.md)
- [Baidu says Wenxin will return to AI’s top tier, targets Hong Kong listing by year-end](https://longbridge.com/en/news/296308374.md)
- [12:30 ETRockbridge Growth Equity Announces Sale of CheckedUp to Providence Equity Partners](https://longbridge.com/en/news/296253550.md)